The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | PALOMA-2: subcutaneous amivantamab Q4W and lazertinib in EGFR+ NSCLC
Nicolas Girard, MD, Institut Curie, Paris, France, discusses the Phase II PALOMA-2 trial (NCT05498428) of first-line subcutaneous amivantamab every 4 weeks (Q4W) with lazertinib in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). The regimen demonstrated high response rates consistent with historical intravenous data, alongside fewer administration-related reactions. Safety outcomes were manageable, with low rates of venous thromboembolism when prophylactic anticoagulation was used. These results suggest a convenient alternative administration route that may enhance treatment experience. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this is PALOMA-2 study, multi-cohort study. Here this is a cohort of patients first line, common EGFR mutation, receiving amivantamab plus lazertinib, as we see in the landmark MARIPOSA trial. Mariposa has just been published in the New England Journal of Medicine, showing the benefit of the combination versus Osimertinib. How to move forward and integrate amivantamab subcutaneous in this regimen? This is a Paloma II cohort with amivantamab...
So this is PALOMA-2 study, multi-cohort study. Here this is a cohort of patients first line, common EGFR mutation, receiving amivantamab plus lazertinib, as we see in the landmark MARIPOSA trial. Mariposa has just been published in the New England Journal of Medicine, showing the benefit of the combination versus Osimertinib. How to move forward and integrate amivantamab subcutaneous in this regimen? This is a Paloma II cohort with amivantamab. Every four weeks, subcutaneous formulation and in combination with lazertinib, integrating the VTE prophylaxis for the first four months and also looking at the outcomes of patients. Exposure to amivantamab was actually similar as expected with the subcutaneous formulation. We have in this cohort of patients a response rate of 83%, very similar to that reported in Mariposa. We see prolonged responses in those patients, median not yet reached, So no duration of response yet, no PFS, no OS. In terms of safety, we see a very low risk of VTE, less than 10%. So in line with what is expected in this patient population. With the subcutaneous formulation of amivantamab, we see a very low risk of infusion-related reaction as expected. In this cohort, the cocoon regimen was not implemented for the dermatologic prophylactic management and we still see some cutaneous adverse events as expected. So this data really shows the value of the subcutaneous formulation of amivantamab, which will be very helpful for the patients, very helpful for the patient care organization at the hospital and support obviously the MARIPOSA regimen as the standard of care for patients with EGFR common mutation.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
